P

Pacific Shuanglin Bio pharmacy Co Ltd
SZSE:000403

Watchlist Manager
Pacific Shuanglin Bio pharmacy Co Ltd
SZSE:000403
Watchlist
Price: 14.68 CNY 0.89%
Market Cap: 14B CNY

Pacific Shuanglin Bio pharmacy Co Ltd
Free Cash Flow

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Pacific Shuanglin Bio pharmacy Co Ltd
Free Cash Flow Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Free Cash Flow CAGR 3Y CAGR 5Y CAGR 10Y
P
Pacific Shuanglin Bio pharmacy Co Ltd
SZSE:000403
Free Cash Flow
-ÂĄ477.2m
CAGR 3-Years
N/A
CAGR 5-Years
-63%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Free Cash Flow
-ÂĄ4.7B
CAGR 3-Years
24%
CAGR 5-Years
5%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Free Cash Flow
-ÂĄ355.1m
CAGR 3-Years
54%
CAGR 5-Years
28%
CAGR 10-Years
N/A
Akeso Inc
HKEX:9926
Free Cash Flow
-ÂĄ1.1B
CAGR 3-Years
13%
CAGR 5-Years
-26%
CAGR 10-Years
N/A
3SBio Inc
HKEX:1530
Free Cash Flow
ÂĄ2.3B
CAGR 3-Years
39%
CAGR 5-Years
13%
CAGR 10-Years
N/A
S
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
Free Cash Flow
-ÂĄ510.9m
CAGR 3-Years
4%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Pacific Shuanglin Bio pharmacy Co Ltd
Glance View

Market Cap
14B CNY
Industry
Biotechnology

In the intricate web of China's burgeoning pharmaceutical landscape, Pacific Shuanglin Bio-Pharmacy Co., Ltd. stands out as a dynamic entity making waves in the biopharmaceutical sector. Founded with a vision to innovate and provide advanced healthcare solutions, the company has anchored its operations in the research, development, manufacturing, and marketing of a diverse range of bio-products and pharmaceutical drugs. The core of their business revolves around biotechnology, leveraging cutting-edge techniques to develop treatments aimed at addressing critical and complex health issues. Their product portfolio is robust, comprising antibiotics, cardiovascular medications, and other critical therapeutic areas, which emphasizes their capacity to adapt and thrive in a competitive market. Central to Pacific Shuanglin's success is its steadfast commitment to research and innovation. By investing heavily in R&D, the company not only ensures a steady pipeline of new products but also enhances the efficacy and safety of existing ones. This strategic focus not only stimulates growth but also fortifies their competitive edge. Their revenue model predominantly hinges on the successful commercialization of these pharmaceutical innovations, reinforcing a cycle of continual improvement and reinvestment in new medical solutions. Through strategic partnerships and a well-established distribution network, Pacific Shuanglin effectively reaches its target markets, both domestically and internationally, ensuring that their advanced medical products make a tangible difference in the lives of patients.

Intrinsic Value
24.69 CNY
Undervaluation 41%
Intrinsic Value
Price
P

See Also

What is Pacific Shuanglin Bio pharmacy Co Ltd's Free Cash Flow?
Free Cash Flow
-477.2m CNY

Based on the financial report for Sep 30, 2025, Pacific Shuanglin Bio pharmacy Co Ltd's Free Cash Flow amounts to -477.2m CNY.

What is Pacific Shuanglin Bio pharmacy Co Ltd's Free Cash Flow growth rate?
Free Cash Flow CAGR 5Y
-63%

Back to Top